PharmacoEconomics & Outcomes News 804, p27 - 2 Jun 2018
Prescription drug expenditure
increasing in USA
Prescription drug expenditure in USA increased in
2017 and is projected to increase further in 2018,
according to findings of a study published in American
Journal of Health-System Pharmacy.
Data from the IQVIA National Sales Perspectives
database were used to assess prescription drug
expenditure (costs of purchases from drug companies)
in USA in 2017. Variables with a potential impact on
prescription drug expenditure in hospitals and clinics in
2018, including new drug approvals and drug patent
expiries, were reviewed, and prescription drug
expenditure in 2018 was projected based on
quantitative analyses and expert opinion.
Total expenditure on prescription drugs in the US
increased by 1.7% between 2016 and 2017, to
455.9 billion. Overall, the drugs with the highest
expenditure were adalimumab ($17.1 billion), insulin
glargine ($9.4 billion) and etanercept ($8.8 billion).
Prescription expenditure decreased by 0.7% in 2017
versus 2016 in nonfederal hospitals, to $34.2 billion
(primarily due to lower utilisation), but increased by
10.9% in clinics, to $70.8 billion.
In 2017, the drugs with the highest expenditure in
clinics were infliximab ($3.7 billion), pegfilgrastim
(3.2 billion) and rituximab ($2.8 billion), while the drugs
with the highest expenditure in nonfederal hospitals
were rituximab, infliximab, alteplase, immune globulin
Total prescription drug expenditure in 2018 was
projected to increase by between 3% and 5% overall,
between 11% and 13.0% in clinics, and up to 2% in
"Health-system pharmacy leaders should carefully
examine their own local drug utilization patterns to
determine their own organization’s anticipated
spending in 2018," said the authors.
Schumock GT, et al. National trends in prescription drug expenditures and
projections for 2018. American Journal of Health-System Pharmacy : 10 May
2018. Available from: URL: http://doi.org/10.2146/ajhp180138
PharmacoEconomics & Outcomes News 2 Jun 2018 No. 8041173-5503/18/0804-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved